Deutsche Bank’s Monopar Therapeutics MNPR Stock Holding History

Deutsche Bank’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.03M	Sell	25,461 -5,547	-18%	-$595K	﹤0.01%	1761
2026 Q2	$2.87M	Buy	31,008 +2,186	+8%	+$135K	﹤0.01%	1702
2026 Q1	$1.58M	Buy	28,822 +25,449	+754%	+$1.54M	﹤0.01%	1915
2025 Q4	$220K	Sell	3,373 -639	-16%	-$52.2K	﹤0.01%	2972
2025 Q3	$328K	Buy	4,012 +627	+19%	+$28K	﹤0.01%	2785
2025 Q2	$121K	Buy	+3,385	New	+$123K	﹤0.01%	3183

Other funds holding MNPR

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Gerber LLC Columbus, Ohio $220M AUM 16.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Deutsche Bank's MNPR Position: Q3 2026 in Review

Deutsche Bank reduced its Monopar Therapeutics (MNPR) stake by 18% in Q3 2026, selling an estimated $595K and leaving 25,461 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1761.

Deutsche Bank first reported a position in MNPR in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.87M in Q2 2026. 23 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

Deutsche Bank held 25,461 shares of Monopar Therapeutics worth $2.03M as of Q3 2026.
Deutsche Bank sold 5,547 Monopar Therapeutics shares in Q3 2026, an estimated $595K.
Monopar Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1761 holding.
Deutsche Bank first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 6 quarters since.
Deutsche Bank's Monopar Therapeutics position peaked at $2.87M in Q2 2026.
23 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.